TORNTPHARM · Pharma & Healthcare · large cap · Nifty Next 50
What the business sold
What it kept after tax
Profit from operations
Cash the operations produced
Borrowings against the business
Paid out per share · not collected yet
Price index · Start = 100 · Dividends excluded · ₹4,965.5 today (+0.72%)
As of 13 Sept 2026
Price to book 20.0
Trailing twelve months
Closing prices
| Reported metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 9,464 | 10,562 | 11,317 | 13,753 |
| Operating profit | 2,140 | 2,572 | 2,926 | 3,440 |
| Net profit | 1,245 | 1,656 | 1,911 | 2,163 |
| Operating cash flow | 2,368 | 3,266 | 2,585 | 3,023 |
| Free cash flow | 1,794 | 2,833 | 1,973 | 2,345 |
| Capital expenditure | -574 | -433 | -612 | -677 |
| Tax expense | 602 | 696 | 762 | 734 |
| Total debt | 5,369 | 4,022 | 3,202 | 15,026 |
| Cash and equivalents | 509 | 835 | 573 | 1,117 |
| Shareholders equity | 6,198 | 6,856 | 7,591 | 8,388 |
| Earnings per share (₹) | 36.79 | 48.94 | 56.47 | 63.92 |
Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.
| Quarter ended | Revenue | Operating profit | Net profit | EPS (₹) |
|---|---|---|---|---|
| 30 Jun 2026 | 4,835 | 1,071 | 566 | 14.87 |
| 31 Mar 2026 | 4,128 | 848 | 389 | 11.51 |
| 31 Dec 2025 | 3,251 | 882 | 635 | 18.77 |
| 30 Sept 2025 | 3,246 | 879 | 591 | 17.45 |
| 30 Jun 2025 | 3,128 | 831 | 548 | 16.19 |
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
The headline states a business fact and a direction that hurts it. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.80. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Somebody's reading of events rather than an event. Worth the argument; not a filing.
Classifier confidence: 0.35. This is not the probability that the report is true.
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Industry: Drug Manufacturers - Specialty & Generic
Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.
Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.
Sign in with Google